NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Price, News & Analysis $6.36 -0.04 (-0.63%) Closing price 04:00 PM EasternExtended Trading$6.36 +0.00 (+0.08%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lifecore Biomedical Stock (NASDAQ:LFCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lifecore Biomedical alerts:Sign Up Key Stats Today's Range$6.36▼$6.3950-Day Range$4.09▼$6.5952-Week Range$3.63▼$8.98Volume780,492 shsAverage Volume288,357 shsMarket Capitalization$241.08 millionP/E RatioN/ADividend YieldN/APrice Target$6.50Consensus RatingReduce Company Overview Lifecore Biomedical, Inc. is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production. Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications. Its capabilities also include manufacturing and filling other complex injectable and parenteral products, including products requiring specialized handling, high-viscosity processing or lyophilization. Headquartered in Chaska, Minnesota, Lifecore serves customers in the United States and international markets. The business was historically associated with Landec Corporation, which acquired Lifecore in 1999; Landec changed its corporate name to Lifecore Biomedical in 2023 as part of a transition toward a healthcare-focused identity.AI Generated. May Contain Errors. Read More Lifecore Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreLFCR MarketRank™: 1.304318579305 of 5 starsLifecore Biomedical scored higher than 26% of companies evaluated by MarketBeat, and ranked 778th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingReduce Consensus RatingLifecore Biomedical has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Lifecore Biomedical is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLifecore Biomedical has only been the subject of 4 research reports in the past 90 days.Read more about Lifecore Biomedical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lifecore Biomedical are expected to decrease in the coming year, from ($1.02) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLifecore Biomedical has a P/B Ratio of 15.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.08% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 2.77, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lifecore Biomedical has recently decreased by 27.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.39 News SentimentLifecore Biomedical has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lifecore Biomedical this week, compared to 3 articles on an average week.Search Interest1 people have searched for LFCR on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders32.68% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lifecore Biomedical's insider trading history. Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LFCR Stock News HeadlinesLifecore's Q3 Loss Widens To $40 Mln As New PPQ Contract GainedNovember 5 at 8:01 AM | rttnews.comLifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate UpdateNovember 4 at 11:57 AM | markets.businessinsider.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 6 at 1:00 AM | Behind the Markets (Ad)Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate UpdateNovember 4 at 7:05 AM | globenewswire.comLifecore Biomedical (LFCR) Expected to Release Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)October 30, 2026 | globenewswire.comLifecore Biomedical, Inc. (LFCR) - What Are Investment Firms Thinking About This Stock?October 30, 2026 | americanbankingnews.comDaiichi Sankyo (OTCMKTS:DSNKY) versus Lifecore Biomedical (NASDAQ:LFCR) Head to Head AnalysisOctober 28, 2026 | americanbankingnews.comSee More Headlines LFCR Stock Analysis - Frequently Asked Questions How have LFCR shares performed this year? Lifecore Biomedical's stock was trading at $8.18 on January 1st, 2026. Since then, LFCR shares have decreased by 22.2% and is now trading at $6.36. How were Lifecore Biomedical's earnings last quarter? Lifecore Biomedical, Inc. (NASDAQ:LFCR) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.78. The firm had revenue of $25.32 million for the quarter, compared to analyst estimates of $25.57 million. Who are Lifecore Biomedical's major shareholders? Lifecore Biomedical's top institutional investors include Allspring Global Investments Holdings LLC (0.44%), Mraz Amerine & Associates Inc. (0.06%) and Covestor Ltd (0.03%). Insiders that own company stock include Wynnefield Partners Small Cap and Paul Josephs. View institutional ownership trends. How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2026Today11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 LFCR's financial health is in the Green zone, according to TradeSmith. LFCR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LFCR CIK1005286 Webwww.lifecore.com Phone(952) 368-4300Fax650-368-9818Employees382Year Founded1965Price Target and Rating Average Price Target for Lifecore Biomedical$6.50 High Price Target$6.50 Low Price Target$6.50 Potential Upside/Downside+2.2%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-56.80% Pretax MarginN/A Return on EquityN/A Return on Assets-29.57% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio2.69 Sales & Book Value Annual Sales$128.87 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book15.14Miscellaneous Outstanding Shares37,906,000Free Float25,518,000Market Cap$241.08 million OptionableOptionable Beta0.99 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:LFCR) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
